James Rider, DO
Geriatric Medicine · Winchester, KSNPI 1215968870
Payments from drug & device makers
Across 608 payments — averaging $133.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$71K
- Organogenesis Inc.$2K
- Sunovion Pharmaceuticals Inc.$793
- Teva Pharmaceuticals USA, Inc.$787
- Neurocrine Biosciences, Inc.$683
- Kerecis Limited$592
- plus $6K from 50 others
What the payments were for
- Consulting fees$8551%
- Speaking & faculty fees$48,40960%
- Travel & lodging$19,79524%
- Food & beverage$11,23614%
- Education$7221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$68,865
- Kerecis SurgiClose$1,268
- Puraply, NuShield, Affinity$898
- Kerecis Omega3 SurgiClose$420
- Kerecis GraftGuide$317
- NUPLAZID$297
- PURAPLY WOUND MATRIX$262
- INGREZZA$256
- COBENFY$246
- Apligraf$147
- Kerecis Omega3 GraftGuide$140
- Kerecis Omega3 Marigen$140
- PuraPly$140
- Briviact$123
- Nayzilam$123
- REXULTI$112
- Austedo XR$106
How this compares
$81,017 in reported general payments places this provider in the 95th percentile of 24 geriatric medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,043 | $401,070 |
| AustedoDeutetrabenazine | 81 | $289,221 |
| Austedo XrDeutetrabenazine | 93 | $284,104 |
| OzempicSemaglutide | 124 | $122,702 |
| Rivastigmine | 611 | $113,999 |
| Invega SustennaPaliperidone Palmitate | 38 | $108,195 |
| RexultiBrexpiprazole | 92 | $76,887 |
| Abilify MaintenaAripiprazole | 25 | $73,523 |
| AptiomEslicarbazepine Acetate | 106 | $73,377 |
| JanuviaSitagliptin Phosphate | 153 | $71,512 |
| JardianceEmpagliflozin | 186 | $63,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $63,686 |
| MyrbetriqMirabegron | 193 | $61,886 |
| ActemraTocilizumab | 13 | $57,425 |
| MounjaroTirzepatide | 54 | $56,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $787 | $573,325174 claims |
| PfizerEliquis, Nurtec Odt | $63 | $423,7121,062 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta | $292 | $179,943158 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $323 | $150,410117 claims |
| Novo NordiskOzempic | $59 | $122,702124 claims |
| Lilly USA, LLCMounjaro, Trulicity | $27 | $113,373105 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $66 | $89,074136 claims |
| AbbVieLinzess, Vraylar | $367 | $75,282119 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $793 | $73,377106 claims |
| Astellas Pharma US IncMyrbetriq | $70,614 | $61,886193 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $221 | $34,489105 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $25,6212,318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 geriatric medicine providers in Kansas.
Other geriatric medicine in Winchester
- Lynda BrumleyMerriam$5K
- Holly CranstonPittsburg$2K
- Nizar KibarAnthony$1K
- Melissa MillsShawnee$939
- Rodney BryantWichita$530
- Rachel MasonKansas City$528
- Bruce HodgesOverland Park$439
- Sumalatha MuthineniKansas City$201
- Shelley AlexanderLeawood$155
- Gregory OdonnellMerriam$114
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.